Últimas noticias sobre Humana (NYSE:HUM) Bolsa

Humana

Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Anthropos Capital Corporation

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

The best traders don't play offense. They play defense. When they trade, they are reactionary. They let the market tell them what to do.
These traders know that the market has a &#8220;memory.&#8221; This means that important support and resistance levels can stay intact for long periods of time. It could be weeks, months — or even years. 
As you can see on the chart, this could be the case with the $225 level for Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>). This is why our team of technical analysis experts has made it our Stock of the Day.
If a stock is trending lower, there isn't enough demand to absorb all of the supply. Sellers are forced to offer their shares out at a discount if they want to find someone to buy them. This action forces the shares into a downtrend.
Downtrends end when they reach support. At support levels, there is enough demand (buy orders) to absorb all of the supply (sell orders).
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-1024x627.png" alt="" class="wp-image-577237" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-1024x627.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-768x470.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3.png 1182w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/news/24/10/41143156/oil-prices-spike-energy-stocks-jump-after-irans-missile-attack-on-israel-what-investors-need-to-know">Oil Prices Spike, Energy Stocks Jump After Iran&#8217;s Missile Attack On Israel: What Investors Need To Know</a>
The $225 level first became support for Humana in April 2019. Then it was support again in March 2020. This was a case of &#8220;market memory.&#8221;
Support can stay intact for extended periods of time because of remorseful or regretful sellers. These are people who sold their shares while they were at support, but regretted doing so after the stock rallied and the price moved higher.
Some of these disappointed sellers vow to buy their shares back. But they will only do so if they can get them at the same price they were sold.
As a result, when the shares eventually return to the support level, they enter buy orders. If there are a large number of these buy orders, it will create support at the level that had been support before.
<a href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit">After some disappointing news</a>, Humana is selling off and once again getting close to the important $225 level. If it does get there, there is a good chance that the market &#8220;remembers&#8221; this level was support before.
This means there is a good chance that it finds a bottom. It also means there is a good chance the stock reverses and rallies off of this level just like it did in April 2019 and March 2020.
Read Next: • <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41147552/bitcoin-drops-below-62-000-as-analysts-warn-of-potential-further-decline">Bitcoin Drops Below $62,000 As Analysts Warn Of Potential Further Decline</a>

Photo: T. Schneider via Shutterstock

Health Care

Technicals

Trading Ideas

Stock Of The Day: Will Humana Remember?

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Wednesday.
The Dow traded up 0.07% to 42,186.44 while the NASDAQ gained 0.24% to 17,952.61. The S&amp;P 500 also rose, gaining, 0.03% to 5,710.22.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41091653/how-to-earn-500-a-month-from-mccormick-stock-ahead-of-q3-earnings">How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Wednesday.
In trading on Wednesday, consumer staples shares dipped by 1%.
Top Headline
ConAgra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) reported weaker-than-expected first-quarter results.
ConAgra reported quarterly adjusted earnings per share of 53 cents, missing the analyst consensus of 60 cents. Net sales of $2.79 billion (down 3.8%) missed the street view of $2.84 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares shot up 25% to $6.02 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) got a boost, surging 7% to $128.37 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 46% to $0.6818. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares dropped 13% to $242.64 after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 34% to $2.35 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 30% to $3.1318. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $70.08 while gold traded down 0.7% at $2,672.80.
Silver traded up 0.8% to $31.980 on Wednesday, while copper rose 1.3% to $4.65.
Euro zone
European shares closed mixed today. The eurozone's STOXX 600 rose 0.05%, Germany's DAX fell 0.25% and France's CAC 40 rose 0.05%. Spain's IBEX 35 Index fell 0.55%, while London's FTSE 100 gained 0.17%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
<ul>
<li>Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.</li>
<li>The EIA said crude oil inventories in the U.S. climbed by 3.889 million barrels for the week ended Sept. 27, versus market estimates of a 1.3 million decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

ADTX

EGRX

JOBY

Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings

Stephens &amp; Co. analyst Scott Fidel downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Overweight to Equal-Weight and lowers the price target from $400 to $250.

Downgrades

Price Target

Analyst Ratings

Stephens & Co. Downgrades Humana to Equal-Weight, Lowers Price Target to $250

Live On CNBC, Steve Weiss Announces Bought Humana

Leerink Partners analyst Whit Mayo downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Outperform to Market Perform and lowers the price target from $400 to $250.

Leerink Partners Downgrades Humana to Market Perform, Lowers Price Target to $250

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 100 points on Wednesday.
The Dow traded up 0.24% to 42,256.16 while the NASDAQ rose 0.27% to 17,958.08. The S&amp;P 500 also rose, gaining, 0.16% to 5,717.63.
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Wednesday.
In trading on Wednesday, real estate shares dipped by 0.9%.
Top Headline
NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) reported mixed first-quarter results on Tuesday.
The company reported first-quarter revenue of $11.59 billion, missing analyst estimates of $11.65 billion. The athletic footwear and apparel company reported first-quarter earnings of 70 cents per share, beating analyst estimates of 52 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares shot up 20% to $5.74 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>Shares of Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) got a boost, surging 10% to $11.77 after the company announced the receipt of several dredging awards totaling $342.3 million.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 38% to $0.6480. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares dropped 18% to $230.39 after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 36% to $2.28 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 31% to $3.05. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $70.22 while gold traded down 0.8% at $2,669.60.
Silver traded up 1% to $32.03 on Wednesday, while copper rose 1% to $4.6350.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.01%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.09%. Spain's IBEX 35 Index fell 0.65%, while London's FTSE 100 gained 0.14%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
<ul>
<li>Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.</li>
<li>The EIA said crude oil inventories in the U.S. climbed by 3.889 million barrels for the week ended Sept. 27, versus market estimates of a 1.3 million decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Intraday Update

GLDD

Dow Gains 100 Points; Joby Aviation Shares Spike Higher

Whales with a lot of money to spend have taken a noticeably bearish stance on Humana.
Looking at options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) we detected 47 trades.
If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 33 are puts, for a total amount of $3,936,662 and 14, calls, for a total amount of $568,563.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $400.0 for Humana over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Humana stands at 304.11, with a total volume reaching 9,185.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Humana, situated within the strike price corridor from $160.0 to $400.0, throughout the last 30 days.
<h3>Humana 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727879545_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$25.0</td>
<td>$23.0</td>
<td>$24.2</td>
<td>$255.00</td>
<td>$847.0K</td>
<td>785</td>
<td style="text-align: right;">757</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$26.3</td>
<td>$24.5</td>
<td>$24.5</td>
<td>$255.00</td>
<td>$612.5K</td>
<td>785</td>
<td style="text-align: right;">257</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$23.0</td>
<td>$19.1</td>
<td>$23.0</td>
<td>$230.00</td>
<td>$575.0K</td>
<td>1.1K</td>
<td style="text-align: right;">95</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.3</td>
<td>$9.6</td>
<td>$10.3</td>
<td>$210.00</td>
<td>$257.5K</td>
<td>46</td>
<td style="text-align: right;">290</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$12.2</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$205.00</td>
<td>$228.0K</td>
<td>0</td>
<td style="text-align: right;">222</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,640,114, the HUM's price is down by -17.04%, now at $231.83. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $396.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $395. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Humana with a target price of $400. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $395. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $395.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Humana Options Trading: A Deep Dive into Market Sentiment

According to preliminary data from the Centers for Medicare and Medicaid Services (CMS), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) faces a substantial drop in its Medicare Advantage (MA) <a target="_blank" href="https://www.benzinga.com/quote/hum" rel="noreferrer noopener">Star Ratings for 2025</a>.
The data available in the CMS Plan Finder as of October 1, 2024, reveals that only 25% of Humana&#8217;s members are enrolled in plans rated four stars and above, a sharp decline from 94% in 2024.
The decrease is primarily driven by contract H5216, which holds around 45% of Humana&#8217;s MA membership and 90% of its employer group waiver plan (Group MA) membership.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.
H5216&#8217;s <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000049071/000004907124000045/hum-20241002.htm" rel="noreferrer noopener">rating</a> dropped to 3.5 stars from 4.5 stars, affecting the company&#8217;s quality bonus payments in 2026. CMS is expected to release the official 2025 Star Ratings around October 10.
Humana attributes the lower star ratings to narrowly missing higher industry benchmarks based on a few key measures.
The company has raised concerns regarding potential errors in CMS&#8217;s calculation of certain results and industry thresholds. While appeals are still pending, Humana has requested further clarification from CMS to ensure the accuracy of its ratings.
The company plans to engage closely with CMS to address these issues and ensure that the Star Ratings accurately reflect the quality of its plans.
Despite its efforts to appeal the results, Humana expressed disappointment with its 2025 performance. It has launched initiatives to improve operational discipline and reclaim its leadership position in MA Star Ratings.
Humana expects the changes to drive improvements in key performance areas and positively impact quality bonus payments by 2027.
Looking ahead, Humana is exploring options to mitigate the potential revenue loss anticipated in 2026 due to the drop in Star Ratings.
It does not expect these ratings to affect its financial outlook for 2024 or 2025. Humana reaffirmed 2024 adjusted EPS of ~$16.00 versus the consensus of $20.31. Humana expects a 2024 insurance segment benefit <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40070046/insurance-giant-humana-stock-tumbles-after-q2-earnings-beat-issues-sub-par-profit-outlook" rel="noreferrer noopener">ratio of approximately 90%</a>.
However, while Humana remains focused on achieving its goal of a 3% margin in individual MA by 2027, the likelihood of meeting this target has become more uncertain due to the 2025 ratings outcome.
Price Action: HUM stock is down 20.10% at $223.23 during the premarket session at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation</a>.</li>
</ul>
Photo: T. Schneider via Shutterstock

Government

Large Cap

Movers

General

Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit

HUM: -25% &#x7C; <a href="https://www.benzinga.com//node/41137484">Humana shares are trading lower after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</a>
&nbsp;
NKE: -8% &#x7C; <a href="https://www.benzinga.com//node/41138743">Nike shares are trading lower after the company missed Q1 revenue estimates.</a>
&nbsp;
TGL: 74% &#x7C; <a href="https://www.benzinga.com//node/41138720">Treasure Global shares are trading higher after the company announced that it has completed its previously disclosed at-the-market equity offering program.</a>

Market-Moving News for October 2nd

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Wednesday.
Shares of NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell sharply in today's pre-market trading f<a href="https://www.benzinga.com/news/earnings/24/10/41129610/nike-q1-earnings-revenue-miss-eps-beat-teams-energized-amid-ceo-transition-a-comeback-at-this-scale">ollowing first-quarter results</a>.
The company reported first-quarter revenue of $11.59 billion, missing analyst estimates of $11.65 billion. The athletic footwear and apparel company reported first-quarter earnings of 70 cents per share, beating analyst estimates of 52 cents per share.
NIKE shares declined 5.5% to $84.25 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares declined 24% to $212.77 in pre-market trading after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>TC Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRP#NYSE">TRP</a>) dipped 7.1% to $44.94 in pre-market trading. TC Energy provided conversion right and dividend rate notice for Series 9 and 10 preferred shares.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) shares fell 6.9% to $9.31 in pre-market trading after dipping over 15% on Tuesday.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) shares declined 6% to $18.00 in pre-market trading.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares fell 4.5% to $62.00 in pre-market trading. The company reported better-than-expected earnings for its third quarter and announced plans to cut approximately 4% of the global workforce and eliminate unfilled job positions.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares declined 4.4% to $0.7290 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 3.4% to $14.50 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>

Pre-Market Outlook

ALHC

BLCO

CAPR

LILM

Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock moved upwards by 19.9% to $1.17 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares rose 17.4% to $17.0. The company's market cap stands at $242.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 11.81% to $0.23. The market value of their outstanding shares is at $5.5 million. </li>
<li>Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) stock moved upwards by 9.72% to $3.95. The company's market cap stands at $1.0 billion. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock rose 9.3% to $0.33. The company's market cap stands at $23.6 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 8.49% to $1.15. The market value of their outstanding shares is at $29.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares declined by 21.8% to $218.63 during Wednesday's pre-market session. The company's market cap stands at $26.3 billion. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock fell 12.63% to $0.38. The market value of their outstanding shares is at $7.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 11.87% to $0.22. The market value of their outstanding shares is at $1.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock declined by 11.03% to $1.21. The company's market cap stands at $15.5 million. </li>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares declined by 9.18% to $13.17. The market value of their outstanding shares is at $781.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 8.22% to $0.51. The market value of their outstanding shares is at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUTL

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTCX

ERNA

IGMS

KAPA

MHUA

MODV

SLXN

TIVC

XAIR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Humana shares are trading lower after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.

Despite on-going appeal efforts, the Company is disappointed with its performance and has initiatives underway focused on improving its operating discipline and returning to an industry leading Stars position as quickly as possible. These initiatives are expected to impact performance across key measures and drive improved quality bonus payments in 2027 and beyond.
In addition, the Company remains focused on achieving its individual MA margin target of &lsquo;at least 3 percent&rsquo;, although there is now more risk in its ability to fully achieve this result by 2027.

Humana Expects 2025 Stars Results Not To Impact Financial Results Or Outlook For 2024 Or 2025

Based on preliminary 2025 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS), which became available in CMS Plan Finder as of October 1, 2024, Humana Ihas approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in 2024.
A significant driver of these results was contract H5216 decreasing to a 3.5-star rating from a 4.5-star rating in 2024.&nbsp;The decline in Stars performance for 2025 will impact Humana&rsquo;s quality bonus payments in 2026. 2025 Star rating details are expected to be formally released by CMS on or around October 10th.

Guidance

Humana Says Exploring All Available Options To Mitigate Expected 2026 Revenue Headwind Related To Its 2025 Star Ratings In The Event Its Challenges To Results Are Unsuccessful - FIling

Throughout the last three months, 12 analysts have evaluated Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $388.0, a high estimate of $407.00, and a low estimate of $349.00. Surpassing the previous average price target of $374.08, the current average has increased by 3.72%.
<img src="https://www.benzinga.com/files/images/story/2024/1727798465_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Humana among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$396.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$349.00</td>
<td>$341.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$364.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$407.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$400.00</td>
<td>$355.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Humana's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>Discovering Humana: A Closer Look</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Financial Insights: Humana</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Humana's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 2.3%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.14%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: Humana's debt-to-equity ratio surpasses industry norms, standing at 0.77. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Humana

Cantor Fitzgerald analyst Sarah James reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and maintains $395 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $395 Price Target

Humana Reveals Its Medicare Advantage And Medicare Prescription Drug Plan Offerings For 2025

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 3.4% on an annualized basis producing an average annual return of 15.43%. Currently, Humana has a market capitalization of $38.48 billion. 
Buying $1000 In HUM: If an investor had bought $1000 of HUM stock 15 years ago, it would be worth $8,712.38 today based on a price of $319.57 for HUM at the time of writing.
<h3>Humana's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727472623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $8,700 Today

With the stock markets trading near highs again and the start of a lower interest rates cycle, the backdrop for mergers, spin-offs, and acquisitions continues to improve. Elevated stock prices are just as good as currency when trying to acquire another company. The Sept. 24, 2024, announcement that Smartsheet Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smar#NYSE">SMAR</a>) will be acquired by Blackstone and Vista Equity Partners for $56.50 per share or $8.4 billion is a prime example of the improving backdrop.
Prior to the news, plenty of speculation and rumors were swirling around about the work collaboration software provider. Investors looking for another potential and logical buyout candidate in the healthcare sector can take a close look at Surgery Partners Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgry#NASDAQ">SGRY</a>).
<h2>The Acute Care Boom Is Real, and Health Insurers Are Scrambling</h2>
The acute care boom has been a growth driver for Surgery Partners, which owns and operates surgical hospitals, centers and ambulatory facilities, providing high-quality care at lower prices than general hospitals. The acute care surge that started in the fall of 2023 shocked health insurers like Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>), causing them to lower their earnings forecasts for the next two years. There was a significant rise in inpatient utilization from their Medicare Advantage members.
Due to the significantly lower prices, patients and insurance carriers prefer non-emergency procedures to be often handled at these specialized facilities rather than acute care hospitals. Their specialized facilities have lower overhead, more efficiency and less complexity.
Procedures performed at surgical centers can cost 50% less than at a traditional hospital. Many of these facilities have already negotiated rates with the major insurers, resulting in lower out-of-pocket expenses for the patients as well. Due to the lower costs, health insurance companies prefer outpatient surgical centers and ambulatory facilities over hospitals.
<h2>Surgery Partners Raises 2024 Revenue Forecast</h2>
Surgery Partners reported their second-quarter 2024 EPS of 21 cents, beating analyst expectations by a penny. Revenues rose 14.2% YoY to $762.1 million, beating consensus estimates of $735.94 million. The key metrics were strong as same-facility revenues grew 10% YoY, and same-facility cases rose 3.9% YoY. The company raised its full-year 2024 revenue forecast to at least $3.075 billion, beating consensus estimates of $3.06 billion.
<h2>Takeover Speculation Makes Sense for Integrated Health Care Transformation</h2>
Insurance carriers love Surgery Partners so much that there is speculation that UnitedHealth Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) may be interested in acquiring them. Private equity firms are also very interested in the nation&#39;s third-largest ambulatory surgical center (ABC) operator. As more insurers evolve into integrated healthcare companies like Kaiser Permanente and as CVS Health Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvs#NYSE">CVS</a>) did with its acquisition of Aetna Health Insurance, interest in Surgery Partners will continue to grow. Bain Capital is Surgery Partners&#39; largest shareholder, with a 39% stake.
<h2>SGRY Is Forming an Ascending Triangle Breakout </h2>
An ascending triangle pattern is comprised of a flat-top horizontal upper trendline resistance converging with an ascending (rising) lower trendline support to meet at the apex point. The breakout occurs when the stock surges through the upper trendline, and a breakdown occurs when the stock falls below the rising trendline.
<img alt="Surgery Partners SGRY stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240924103837_chartq-sgry.jpg" style="height:785px; width:915px" />
SGRY formed the flat-top upper trendline resistance at $33.95 after it deflected two breakout attempts. This pushed shares to the rising lower trendline and indicated growing demand as buyers raised their bids. The anchored daily VWAP support is at $29.15. SGRY continues to move closer to the apex point, where it can break out through the $33.95 upper trendline or fall below the $31.75 lower trendline.
The daily relative strength index (RSI) is stalled at the 58-band. Fibonacci (Fib) pullback support levels are at $31.08, $29.95, $28.35, and $25.78.
Surgery Partners&#39; average consensus price target is $39.86, and its highest analyst price target is $50.00. &nbsp;
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/heres-why-surgery-partners-could-be-the-next-hot-takeover/">Here&#39;s Why Surgery Partners Could Be the Next Hot Takeover</a>&quot; first appeared on MarketBeat.

Earnings Beats

Mid Cap

Rumors

SGRY

SMAR

Here's Why Surgery Partners Could Be the Next Hot Takeover

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 35% bearish. Among these notable options, 8 are puts, totaling $417,304, and 9 are calls, amounting to $508,503.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $350.0 for Humana during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $250.0 to $350.0 over the preceding 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727196343_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$18.2</td>
<td>$17.6</td>
<td>$18.0</td>
<td>$310.00</td>
<td>$126.0K</td>
<td>543</td>
<td style="text-align: right;">78</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$11.3</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$340.00</td>
<td>$107.5K</td>
<td>290</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$53.7</td>
<td>$52.9</td>
<td>$53.65</td>
<td>$350.00</td>
<td>$85.8K</td>
<td>255</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.0</td>
<td>$28.6</td>
<td>$28.6</td>
<td>$320.00</td>
<td>$85.8K</td>
<td>366</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$290.00</td>
<td>$59.9K</td>
<td>1.2K</td>
<td style="text-align: right;">186</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>With a trading volume of 402,787, the price of HUM is up by 0.03%, reaching $312.87.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $396.6666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Humana, which currently sits at a price target of $400. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $395. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $395. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Looking At Humana's Recent Unusual Options Activity

Biggest stock movers Wednesday: TSLA, CIEN, NKE, LW, and more

4 stocks to watch on Wednesday: TSLA, HUM and more

Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3

Humana: 2026 Earnings Likely To Be Crushed

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares were getting hit hard for the second day in a row today after falling by 12% in Tuesday's session and hitting a 52-week lo...

J.P. Morgan Weighs in on Humana Stock Following Medicare Star Rating Changes

Humana Star Ratings plunge is latest in recent Medicare setbacks

Stocks are pushing higher midday, shrugging off a morning in red ink.

Dow Paring Nike Selloff, Oil Price Surge

Wall Street Lunch: Humana Shares Hit Hard

Humana (HUM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Baxter from Wells Fargo ...

Buy Rating Affirmed: Humana's Proactive Strategies to Mitigate Earnings Headwinds

Analyst Erin Wright of Morgan Stanley maintained a Hold rating on Humana (HUM – Research Report), with a price target of $374.00. Erin Wright's rat...

Humana's Star Rating Decline Prompts Hold Rating Amid Financial Uncertainty

CIEN

DXCM

MRNA

NKLA

SMCI

SOLV

TSLA

Press Releases

Humana and Evergreen Nephrology Introduce New Specialized Care Program for Patients Living with Kidney Disease

New Study from Humana Healthcare Research and Harvard University Reveals Better Access to Primary Care for Seniors Receiving Care from Senior-Focused Primary Care Organizations

Humana Earns 2024 Great Place To Work Certification

Texas A&M University Mays Business School and Humana Launch Annual Nationwide Healthcare Analytics Case Competition

Humana and Interwell Health Announce Addition of State of Florida to Value-based Kidney Care Program

New Health Webinars From CenterWell and Conviva Empower Seniors to Take Active Role in Their Health

Humana Inc. to Release Third Quarter 2024 Results on October 30, 2024

Humana's 2025 Medicare Advantage Plans Focus on Quality, Affordable Healthcare Tailored to the Needs of Consumers

Humana Foundation Donates $1 Million to Support Disaster Recovery in the Wake of Hurricane Helene

HUM Investors Have Opportunity to Join Humana Inc. Fraud Investigation with the Schall Law Firm

Comments

Humana

Noticias

Últimas noticias sobre Humana (NYSE:HUM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL